Accéder au contenu
Merck
Toutes les photos(1)

Documents

1095506

USP

Carbidopa

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

(S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropionic acid monohydrate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C10H14N2O4 · H2O
Numéro CAS:
38821-49-7
Poids moléculaire :
244.24
Numéro MDL:
MFCD00889211
Code UNSPSC :
41116107
ID de substance PubChem :
329749233
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

carbidopa

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

O.C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O

InChI

1S/C10H14N2O4.H2O/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H2/t10-;/m0./s1

Clé InChI

QTAOMKOIBXZKND-PPHPATTJSA-N

Informations sur le gène

human ... DDC(1644)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Carbidopa USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Carbidopa and Levodopa Extended-Release Tablets
  • Carbidopa and Levodopa Orally Disintegrating Tablets
  • Carbidopa and Levodopa Tablets

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H319

Classification des risques

Acute Tox. 4 Oral - Eye Irrit. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 7

1 of 7

USP

USP

1361010

Levadopa Related Compound A

Levodopa European Pharmacopoeia (EP) Reference Standard

L0400000

Levodopa

Levodopa Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1271

Levodopa

Levodopa British Pharmacopoeia (BP) Reference Standard

BP213

Levodopa

L-Dopa-(phenyl-d3) ≥98 atom % D, ≥98% (CP)

Sigma-Aldrich

333786

L-Dopa-(phenyl-d3)

3,4-Dihydroxy-L-phenylalanine ≥98% (TLC)

Sigma-Aldrich

D9628

3,4-Dihydroxy-L-phenylalanine

Dopamine hydrochloride

Sigma-Aldrich

H8502

Dopamine hydrochloride

Mohseni Mehran S M et al.
Journal of clinical and diagnostic research : JCDR, 7(6), 1004-1007 (2013-08-02)
According to many studies, sprouted fava beans are a rich source of levo-dihydroxy phenylalanine (L-dopa) the precursor of dopamine, and they are now being investigated for use in the management of Parkinson's disease. The addition of Carbidopa (C-dopa) can reduce
Q. Alan Xu, Timothy L. Madden
Analytical Methods for Therapeutic Drug Monitoring and Toxicology, 80-80 (2011)
Ina Schabram et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 34(44), 14769-14776 (2014-10-31)
Methylphenidate (MPH) inhibits the reuptake of dopamine and noradrenaline. PET studies with MPH challenge show increased competition at postsynaptic D2/3-receptors, thus indirectly revealing presynaptic dopamine release. We used [(18)F]fluorodopamine ([(18)F]FDOPA)-PET in conjunction with the inlet-outlet model (IOM) of Kumakura et
Robert A Hauser
Expert review of neurotherapeutics, 12(2), 133-140 (2012-02-01)
Levodopa (LD) remains the most effective medication to treat Parkinson's disease (PD). However, most patients develop motor fluctuations and dyskinesias with long-term LD use. It is thought that these response complications are due, at least in part, to LD's short
A Castro et al.
Neurologia (Barcelona, Spain), 20(4), 180-188 (2005-05-14)
Levodopa remains the mainstay treatment for Parkinson's disease (PD). Chronic treatment is associated with motor complications (MC) that marred the clinical benefit of levodopa. These problems and experimental data in cell cultures indicating a neurotoxic effect of levodopa have led
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique